\begin{center}
\begin{scriptsize}
\begin{longtable}
{l>{\raggedright}p{2.5cm}>{\raggedright}p{1.5cm}l>{\raggedright}p{1.5cm}lll}
\caption{Fischer exact test for association between genotypes and phenotypic features. $\complement$: set complement of a variant predicate. E.g. $\complement$ for a “missense” predicate includes any mutation that is \textit{not} missense.
}\label{tab:hpo_fet} \\
\hline
\multicolumn{1}{c}{\textbf{Cohort}} & \multicolumn{1}{c}{\textbf{HPO}} & \multicolumn{1}{c}{\textbf{Genotype A}} & \multicolumn{1}{c}{\textbf{}} & \multicolumn{1}{c}{\textbf{Genotype B}} & \multicolumn{1}{c}{\textbf{}} & \multicolumn{1}{c}{\textbf{p-val}} & \multicolumn{1}{c}{\textbf{adj. p}}\\ \hline
\endfirsthead
\multicolumn{8}{c}%

{{\bfseries \tablename\ \thetable{} -- continued from previous page}} \\ 

\hline
\multicolumn{1}{c}{\textbf{Cohort}} & \multicolumn{1}{c}{\textbf{HPO}} & \multicolumn{1}{c}{\textbf{Genotype A}} & \multicolumn{1}{c}{\textbf{}} & \multicolumn{1}{c}{\textbf{Genotype B}} & \multicolumn{1}{c}{\textbf{}} & \multicolumn{1}{c}{\textbf{p-val}} & \multicolumn{1}{c}{\textbf{adj. p}}\\ \hline
\endhead 
\hline \multicolumn{8}{|r|}{{Continued on next page}} \\ \hline 

\endfoot 
\hline \hline 
\endlastfoot 
BRD4 & Intrauterine growth retardation [HP:0001511] & NIPBL & 37/45 (82\%) & BRD4 & 2/9 (22\%) & $9.4 \times 10^{-04}$ & 0.032\\
EHMT1 & Attention deficit hyperactivity disorder [HP:0007018] & N Term Frameshift & 4/8 (50\%) & $^{\complement}$ & 3/96 (3\%) & $4.8 \times 10^{-04}$ & 0.029\\
FBN1 & Disproportionate tall stature [HP:0001519] & TB domain & 2/40 (5\%) & cbEGF & 12/43 (28\%) & 0.007 & 0.029\\
FBN1 & Ectopia lentis [HP:0001083] & TB domain & 9/18 (50\%) & cbEGF & 48/59 (81\%) & 0.013 & 0.038\\
FBN1 & Mitral valve prolapse [HP:0001634] & TB domain & 1/28 (4\%) & cbEGF & 13/47 (28\%) & 0.012 & 0.038\\
FBN1 & Proportionate short stature [HP:0003508] & TB domain & 20/36 (56\%) & cbEGF & 0/24 (0\%) & $2.3 \times 10^{-06}$ & $2.3 \times 10^{-05}$\\
FBN1 & Severe short stature [HP:0003510] & TB domain & 15/36 (42\%) & cbEGF & 0/24 (0\%) & $1.4 \times 10^{-04}$ & $9.0 \times 10^{-04}$\\
FBN1 & Short stature [HP:0004322] & TB domain & 23/39 (59\%) & cbEGF & 0/24 (0\%) & $4.4 \times 10^{-07}$ & $8.8 \times 10^{-06}$\\
FBN1 & Tall stature [HP:0000098] & TB domain & 7/38 (18\%) & cbEGF & 21/40 (52\%) & 0.002 & 0.011\\
FBN1 & Arachnodactyly [HP:0001166] & exon 37 & 0/8 (0\%) & $^{\complement}$ & 52/95 (55\%) & 0.003 & 0.019\\
FBN1 & Ectopia lentis [HP:0001083] & exon 37 & 1/9 (11\%) & $^{\complement}$ & 78/100 (78\%) & $1.1 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
FBN1 & Stiff skin [HP:0030053] & exon 37 & 8/9 (89\%) & $^{\complement}$ & 0/50 (0\%) & $4.1 \times 10^{-09}$ & $8.5 \times 10^{-08}$\\
FBN1 & Hyperextensibility of the finger joints [HP:0001187] & fs last two & 2/2 (100\%) & $^{\complement}$ & 1/90 (1\%) & $7.2 \times 10^{-04}$ & 0.012\\
FBN1 & Arachnodactyly [HP:0001166] & missense & 34/81 (42\%) & $^{\complement}$ & 18/22 (82\%) & $1.0 \times 10^{-03}$ & 0.026\\
FBN1 & Hyperextensibility of the finger joints [HP:0001187] & missense & 0/78 (0\%) & $^{\complement}$ & 3/14 (21\%) & 0.003 & 0.026\\
FBN1 & Thoracic aortic aneurysm [HP:0012727] & missense & 25/64 (39\%) & $^{\complement}$ & 12/14 (86\%) & 0.002 & 0.026\\
FBXL4 & Feeding difficulties [HP:0011968] & missense/ $^{\complement}$ OR $^{\complement}$/ $^{\complement}$ & 23/24 (96\%) & missense/ missense & 13/27 (48\%) & $1.7 \times 10^{-04}$ & 0.010\\
FGD1 & Broad foot [HP:0001769] & missense & 1/7 (14\%) & $^{\complement}$ & 14/15 (93\%) & $6.2 \times 10^{-04}$ & 0.032\\
GLI3 & Anal atresia [HP:0002023] & Fs in mid region or splice & 7/25 (28\%) & $^{\complement}$ & 3/57 (5\%) & 0.007 & 0.036\\
GLI3 & Nail dysplasia [HP:0002164] & Fs in mid region or splice & 7/20 (35\%) & $^{\complement}$ & 2/54 (4\%) & $1.0 \times 10^{-03}$ & 0.009\\
GLI3 & Preaxial foot polydactyly [HP:0001841] & Fs in mid region or splice & 5/25 (20\%) & $^{\complement}$ & 32/57 (56\%) & 0.003 & 0.021\\
GLI3 & Y-shaped metacarpals [HP:0006042] & Fs in mid region or splice & 11/23 (48\%) & $^{\complement}$ & 4/56 (7\%) & $9.9 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
GLI3 & Y-shaped metatarsals [HP:0010567] & Fs in mid region or splice & 11/19 (58\%) & $^{\complement}$ & 4/50 (8\%) & $3.2 \times 10^{-05}$ & $7.8 \times 10^{-04}$\\
GLI3 & Anal atresia [HP:0002023] & Truncating variants in Exon 15 & 8/28 (29\%) & $^{\complement}$ & 2/54 (4\%) & 0.002 & 0.017\\
GLI3 & Macrocephaly [HP:0000256] & Truncating variants in Exon 15 & 13/16 (81\%) & $^{\complement}$ & 15/42 (36\%) & 0.003 & 0.017\\
GLI3 & Postaxial foot polydactyly [HP:0001830] & Truncating variants in Exon 15 & 9/20 (45\%) & $^{\complement}$ & 2/35 (6\%) & $8.9 \times 10^{-04}$ & 0.011\\
GLI3 & Preaxial foot polydactyly [HP:0001841] & Truncating variants in Exon 15 & 7/28 (25\%) & $^{\complement}$ & 30/54 (56\%) & 0.010 & 0.050\\
GLI3 & Syndactyly [HP:0001159] & Truncating variants in Exon 15 & 5/17 (29\%) & $^{\complement}$ & 33/38 (87\%) & $4.8 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
GLI3 & Macrocephaly [HP:0000256] & Variants in C-terminal third & 13/15 (87\%) & $^{\complement}$ & 15/43 (35\%) & $7.3 \times 10^{-04}$ & 0.004\\
GLI3 & Postaxial foot polydactyly [HP:0001830] & Variants in C-terminal third & 9/16 (56\%) & $^{\complement}$ & 2/39 (5\%) & $7.3 \times 10^{-05}$ & 0.002\\
GLI3 & Postaxial hand polydactyly [HP:0001162] & Variants in C-terminal third & 15/16 (94\%) & $^{\complement}$ & 21/49 (43\%) & $3.4 \times 10^{-04}$ & 0.003\\
GLI3 & Syndactyly [HP:0001159] & Variants in C-terminal third & 5/16 (31\%) & $^{\complement}$ & 33/39 (85\%) & $2.2 \times 10^{-04}$ & 0.003\\
IKZF1 & Recurrent pneumonia [HP:0006532] & p.Asn159Ser & 7/9 (78\%) & $^{\complement}$ & 7/39 (18\%) & $1.0 \times 10^{-03}$ & 0.035\\
IKZF1 & T-cell acute lymphoblastic leukemias [HP:0006727] & p.Asn159Ser & 3/13 (23\%) & $^{\complement}$ & 0/69 (0\%) & 0.003 & 0.047\\
ITPR1 & Aniridia [HP:0000526] & GS Hotspot & 14/20 (70\%) & $^{\complement}$ & 6/48 (12\%) & $6.1 \times 10^{-06}$ & $1.6 \times 10^{-04}$\\
ITPR1 & Delayed ability to sit [HP:0025336] & GS Hotspot & 13/13 (100\%) & $^{\complement}$ & 40/68 (59\%) & 0.003 & 0.030\\
ITPR1 & Delayed ability to walk [HP:0031936] & GS Hotspot & 14/14 (100\%) & $^{\complement}$ & 40/67 (60\%) & 0.003 & 0.030\\
ITPR1 & Delayed gross motor development [HP:0002194] & GS Hotspot & 18/18 (100\%) & $^{\complement}$ & 57/83 (69\%) & 0.005 & 0.032\\
ITPR1 & Motor delay [HP:0001270] & GS Hotspot & 19/19 (100\%) & $^{\complement}$ & 68/94 (72\%) & 0.006 & 0.032\\
ITPR1 & Aniridia [HP:0000526] & IP3 binding & 0/14 (0\%) & $^{\complement}$ & 20/54 (37\%) & 0.007 & 0.024\\
ITPR1 & Delayed ability to sit [HP:0025336] & IP3 binding & 11/11 (100\%) & $^{\complement}$ & 42/70 (60\%) & 0.013 & 0.043\\
ITPR1 & Delayed ability to walk [HP:0031936] & IP3 binding & 13/13 (100\%) & $^{\complement}$ & 41/68 (60\%) & 0.004 & 0.019\\
ITPR1 & Delayed gross motor development [HP:0002194] & IP3 binding & 18/18 (100\%) & $^{\complement}$ & 57/83 (69\%) & 0.005 & 0.024\\
ITPR1 & Delayed speech and language development [HP:0000750] & IP3 binding & 13/13 (100\%) & $^{\complement}$ & 37/63 (59\%) & 0.003 & 0.019\\
ITPR1 & Motor delay [HP:0001270] & IP3 binding & 24/24 (100\%) & $^{\complement}$ & 63/89 (71\%) & 0.002 & 0.019\\
ITPR1 & Neurodevelopmental delay [HP:0012758] & IP3 binding & 29/29 (100\%) & $^{\complement}$ & 70/90 (78\%) & 0.003 & 0.019\\
ITPR1 & Nystagmus [HP:0000639] & IP3 binding & 25/26 (96\%) & $^{\complement}$ & 53/78 (68\%) & 0.003 & 0.019\\
ITPR1 & Delayed ability to sit [HP:0025336] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 53/62 (85\%) & $4.6 \times 10^{-12}$ & $1.7 \times 10^{-11}$\\
ITPR1 & Delayed ability to walk [HP:0031936] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 54/62 (87\%) & $1.5 \times 10^{-12}$ & $7.6 \times 10^{-12}$\\
ITPR1 & Delayed gross motor development [HP:0002194] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 75/82 (91\%) & $4.0 \times 10^{-15}$ & $3.0 \times 10^{-14}$\\
ITPR1 & Delayed speech and language development [HP:0000750] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 50/57 (88\%) & $1.7 \times 10^{-12}$ & $7.6 \times 10^{-12}$\\
ITPR1 & Global developmental delay [HP:0001263] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 48/57 (84\%) & $1.8 \times 10^{-11}$ & $5.7 \times 10^{-11}$\\
ITPR1 & Motor delay [HP:0001270] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 87/94 (93\%) & $3.9 \times 10^{-16}$ & $4.3 \times 10^{-15}$\\
ITPR1 & Neurodevelopmental delay [HP:0012758] & SV Deletion & 0/19 (0\%) & $^{\complement}$ & 99/100 (99\%) & $4.1 \times 10^{-21}$ & $9.0 \times 10^{-20}$\\
ITPR1 & Nystagmus [HP:0000639] & SV Deletion & 17/17 (100\%) & $^{\complement}$ & 61/87 (70\%) & 0.006 & 0.016\\
KCNH5 & Epileptic encephalopathy [HP:0200134] & Arg327His & 15/15 (100\%) & Arg333His & 0/3 (0\%) & $1.0 \times 10^{-03}$ & 0.032\\
KDM6A & Pulmonic stenosis [HP:0001642] & p.Asn891ValfsTer27 & 2/2 (100\%) & $^{\complement}$ & 0/59 (0\%) & $5.5 \times 10^{-04}$ & 0.016\\
LMNA & Distal muscle weakness [HP:0002460] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 36/97 (37\%) & 0.002 & 0.004\\
LMNA & Elevated hemoglobin A1c [HP:0040217] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 79/110 (72\%) & $5.7 \times 10^{-08}$ & $6.8 \times 10^{-07}$\\
LMNA & Limb muscle weakness [HP:0003690] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 38/99 (38\%) & 0.002 & 0.004\\
LMNA & Lipodystrophy [HP:0009125] & Gly608= & 15/15 (100\%) & $^{\complement}$ & 127/236 (54\%) & $1.9 \times 10^{-04}$ & $7.5 \times 10^{-04}$\\
LMNA & Muscle weakness [HP:0001324] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 63/124 (51\%) & $6.1 \times 10^{-05}$ & $3.6 \times 10^{-04}$\\
LMNA & Proximal muscle weakness [HP:0003701] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 53/114 (46\%) & $3.6 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
LMNA & Proximal muscle weakness in upper limbs [HP:0008997] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 35/102 (34\%) & 0.005 & 0.007\\
LMNA & Upper limb muscle weakness [HP:0003484] & Gly608= & 0/15 (0\%) & $^{\complement}$ & 35/96 (36\%) & 0.003 & 0.004\\
LMNA & Achilles tendon contracture [HP:0001771] & Upstream Tail (1-383) & 17/81 (21\%) & $^{\complement}$ & 23/34 (68\%) & $3.4 \times 10^{-06}$ & $1.4 \times 10^{-05}$\\
LMNA & Atrioventricular block [HP:0001678] & Upstream Tail (1-383) & 17/35 (49\%) & $^{\complement}$ & 8/117 (7\%) & $1.2 \times 10^{-07}$ & $1.5 \times 10^{-06}$\\
LMNA & Dilated cardiomyopathy [HP:0001644] & Upstream Tail (1-383) & 35/69 (51\%) & $^{\complement}$ & 5/103 (5\%) & $2.2 \times 10^{-12}$ & $4.2 \times 10^{-11}$\\
LMNA & Elbow contracture [HP:0034391] & Upstream Tail (1-383) & 17/79 (22\%) & $^{\complement}$ & 22/30 (73\%) & $9.6 \times 10^{-07}$ & $7.3 \times 10^{-06}$\\
LMNA & First degree atrioventricular block [HP:0011705] & Upstream Tail (1-383) & 7/62 (11\%) & $^{\complement}$ & 2/116 (2\%) & 0.009 & 0.032\\
LMNA & Foot joint contracture [HP:0008366] & Upstream Tail (1-383) & 17/77 (22\%) & $^{\complement}$ & 23/31 (74\%) & $6.7 \times 10^{-07}$ & $6.4 \times 10^{-06}$\\
LMNA & Hip contracture [HP:0003273] & Upstream Tail (1-383) & 4/79 (5\%) & $^{\complement}$ & 9/30 (30\%) & $1.0 \times 10^{-03}$ & 0.004\\
LMNA & Limb joint contracture [HP:0003121] & Upstream Tail (1-383) & 19/79 (24\%) & $^{\complement}$ & 23/31 (74\%) & $2.1 \times 10^{-06}$ & $9.8 \times 10^{-06}$\\
LMNA & Lipodystrophy [HP:0009125] & Upstream Tail (1-383) & 9/88 (10\%) & $^{\complement}$ & 133/163 (82\%) & $1.7 \times 10^{-29}$ & $6.5 \times 10^{-28}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & Upstream Tail (1-383) & 18/78 (23\%) & $^{\complement}$ & 23/31 (74\%) & $1.5 \times 10^{-06}$ & $8.4 \times 10^{-06}$\\
LMNA & Second degree atrioventricular block [HP:0011706] & Upstream Tail (1-383) & 6/67 (9\%) & $^{\complement}$ & 1/116 (1\%) & 0.010 & 0.032\\
LMNA & Upper-limb joint contracture [HP:0100360] & Upstream Tail (1-383) & 17/77 (22\%) & $^{\complement}$ & 22/30 (73\%) & $1.4 \times 10^{-06}$ & $8.4 \times 10^{-06}$\\
LMNA & Achilles tendon contracture [HP:0001771] & Upstream of NLS & 21/85 (25\%) & $^{\complement}$ & 19/30 (63\%) & $2.7 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
LMNA & Atrioventricular block [HP:0001678] & Upstream of NLS & 17/36 (47\%) & $^{\complement}$ & 8/116 (7\%) & $2.1 \times 10^{-07}$ & $2.7 \times 10^{-06}$\\
LMNA & Dilated cardiomyopathy [HP:0001644] & Upstream of NLS & 35/70 (50\%) & $^{\complement}$ & 5/102 (5\%) & $4.2 \times 10^{-12}$ & $8.0 \times 10^{-11}$\\
LMNA & Elbow contracture [HP:0034391] & Upstream of NLS & 21/83 (25\%) & $^{\complement}$ & 18/26 (69\%) & $1.0 \times 10^{-04}$ & $6.6 \times 10^{-04}$\\
LMNA & First degree atrioventricular block [HP:0011705] & Upstream of NLS & 7/63 (11\%) & $^{\complement}$ & 2/115 (2\%) & 0.010 & 0.033\\
LMNA & Foot joint contracture [HP:0008366] & Upstream of NLS & 21/81 (26\%) & $^{\complement}$ & 19/27 (70\%) & $6.2 \times 10^{-05}$ & $5.9 \times 10^{-04}$\\
LMNA & Hip contracture [HP:0003273] & Upstream of NLS & 4/83 (5\%) & $^{\complement}$ & 9/26 (35\%) & $2.7 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
LMNA & Limb joint contracture [HP:0003121] & Upstream of NLS & 23/83 (28\%) & $^{\complement}$ & 19/27 (70\%) & $1.7 \times 10^{-04}$ & $8.1 \times 10^{-04}$\\
LMNA & Lipodystrophy [HP:0009125] & Upstream of NLS & 10/93 (11\%) & $^{\complement}$ & 132/158 (84\%) & $1.7 \times 10^{-31}$ & $6.6 \times 10^{-30}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & Upstream of NLS & 22/82 (27\%) & $^{\complement}$ & 19/27 (70\%) & $8.2 \times 10^{-05}$ & $6.2 \times 10^{-04}$\\
LMNA & Pancreatitis [HP:0001733] & Upstream of NLS & 4/7 (57\%) & $^{\complement}$ & 14/110 (13\%) & 0.011 & 0.033\\
LMNA & Second degree atrioventricular block [HP:0011706] & Upstream of NLS & 6/68 (9\%) & $^{\complement}$ & 1/115 (1\%) & 0.011 & 0.033\\
LMNA & Upper-limb joint contracture [HP:0100360] & Upstream of NLS & 21/81 (26\%) & $^{\complement}$ & 18/26 (69\%) & $1.2 \times 10^{-04}$ & $6.7 \times 10^{-04}$\\
LMNA & Elevated hemoglobin A1c [HP:0040217] & missense & 73/101 (72\%) & $^{\complement}$ & 6/24 (25\%) & $3.1 \times 10^{-05}$ & $5.9 \times 10^{-04}$\\
LMNA & Loss of truncal subcutaneous adipose tissue [HP:0009002] & missense & 104/104 (100\%) & $^{\complement}$ & 4/11 (36\%) & $7.5 \times 10^{-09}$ & $2.9 \times 10^{-07}$\\
MPV17 & Peripheral axonal neuropathy [HP:0003477] & Pro98Leu/ Pro98Leu & 3/3 (100\%) & $^{\complement}$/$^{\complement}$ OR Pro98Leu/$^{\complement}$ & 1/22 (5\%) & 0.002 & 0.037\\
NBAS & Decreased circulating IgG concentration [HP:0004315] & missense/ missense & 1/12 (8\%) & $^{\complement}$/ $^{\complement}$ OR missense/ $^{\complement}$ & 15/23 (65\%) & 0.002 & 0.035\\
NF1 & Axillary freckling [HP:0000997] & Leu847Pro & 50/61 (82\%) & $^{\complement}$ & 75/193 (39\%) & $3.5 \times 10^{-09}$ & $7.8 \times 10^{-08}$\\
NF1 & Freckling [HP:0001480] & Leu847Pro & 54/54 (100\%) & $^{\complement}$ & 223/301 (74\%) & $5.3 \times 10^{-07}$ & $5.8 \times 10^{-06}$\\
NF1 & Inguinal freckling [HP:0030052] & Leu847Pro & 34/60 (57\%) & $^{\complement}$ & 58/189 (31\%) & $3.9 \times 10^{-04}$ & 0.002\\
NF1 & Lisch nodules [HP:0009737] & Leu847Pro & 22/42 (52\%) & $^{\complement}$ & 61/242 (25\%) & $7.5 \times 10^{-04}$ & 0.003\\
NF1 & Optic nerve glioma [HP:0009734] & Leu847Pro & 15/33 (45\%) & $^{\complement}$ & 24/143 (17\%) & $8.6 \times 10^{-04}$ & 0.003\\
NF1 & Plexiform neurofibroma [HP:0009732] & Leu847Pro & 24/66 (36\%) & $^{\complement}$ & 44/329 (13\%) & $4.6 \times 10^{-05}$ & $3.4 \times 10^{-04}$\\
NF1 & Axillary freckling [HP:0000997] & Met992del & 0/14 (0\%) & $^{\complement}$ & 125/240 (52\%) & $8.6 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
NF1 & Inguinal freckling [HP:0030052] & Met992del & 0/14 (0\%) & $^{\complement}$ & 92/235 (39\%) & 0.003 & 0.008\\
NF1 & Lipoma [HP:0012032] & Met992del & 5/44 (11\%) & $^{\complement}$ & 4/284 (1\%) & 0.003 & 0.008\\
NF1 & Lisch nodules [HP:0009737] & Met992del & 3/36 (8\%) & $^{\complement}$ & 80/248 (32\%) & 0.003 & 0.008\\
NF1 & Plexiform neurofibroma [HP:0009732] & Met992del & 0/44 (0\%) & $^{\complement}$ & 68/351 (19\%) & $2.0 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
NF1 & Scoliosis [HP:0002650] & SV & 18/57 (32\%) & $^{\complement}$ & 38/308 (12\%) & $9.7 \times 10^{-04}$ & 0.017\\
NF1 & Axillary freckling [HP:0000997] & p.Arg1830 & 20/79 (25\%) & $^{\complement}$ & 105/175 (60\%) & $3.7 \times 10^{-07}$ & $2.0 \times 10^{-06}$\\
NF1 & Freckling [HP:0001480] & p.Arg1830 & 76/133 (57\%) & $^{\complement}$ & 201/222 (91\%) & $6.3 \times 10^{-13}$ & $6.9 \times 10^{-12}$\\
NF1 & Inguinal freckling [HP:0030052] & p.Arg1830 & 8/79 (10\%) & $^{\complement}$ & 84/170 (49\%) & $4.9 \times 10^{-10}$ & $3.6 \times 10^{-09}$\\
NF1 & Lisch nodules [HP:0009737] & p.Arg1830 & 11/91 (12\%) & $^{\complement}$ & 72/193 (37\%) & $6.6 \times 10^{-06}$ & $2.9 \times 10^{-05}$\\
NF1 & Neurofibroma [HP:0001067] & p.Arg1830 & 5/8 (62\%) & $^{\complement}$ & 153/162 (94\%) & 0.012 & 0.030\\
NF1 & Optic nerve glioma [HP:0009734] & p.Arg1830 & 0/39 (0\%) & $^{\complement}$ & 39/137 (28\%) & $1.7 \times 10^{-05}$ & $6.3 \times 10^{-05}$\\
NF1 & Plexiform neurofibroma [HP:0009732] & p.Arg1830 & 0/135 (0\%) & $^{\complement}$ & 68/260 (26\%) & $1.7 \times 10^{-14}$ & $3.8 \times 10^{-13}$\\
NF1 & Pulmonic stenosis [HP:0001642] & p.Arg1830 & 13/105 (12\%) & $^{\complement}$ & 5/162 (3\%) & 0.005 & 0.013\\
NF1 & Scoliosis [HP:0002650] & p.Arg1830 & 8/125 (6\%) & $^{\complement}$ & 48/240 (20\%) & $4.0 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
PTPN11 & Hypertelorism [HP:0000316] & missense & 37/41 (90\%) & $^{\complement}$ & 0/12 (0\%) & $6.8 \times 10^{-09}$ & $2.7 \times 10^{-08}$\\
PTPN11 & Intellectual disability, mild [HP:0001256] & missense & 8/23 (35\%) & $^{\complement}$ & 0/12 (0\%) & 0.032 & 0.032\\
PTPN11 & Pulmonic stenosis [HP:0001642] & missense & 18/34 (53\%) & $^{\complement}$ & 0/12 (0\%) & $1.0 \times 10^{-03}$ & 0.002\\
PTPN11 & Webbed neck [HP:0000465] & missense & 15/20 (75\%) & $^{\complement}$ & 0/12 (0\%) & $2.9 \times 10^{-05}$ & $5.9 \times 10^{-05}$\\
RPGRIP1 & Eye poking [HP:0001483] & 1107del/1107del OR 1107del/$^{\complement}$ & 16/16 (100\%) & $^{\complement}$/$^{\complement}$ & 19/41 (46\%) & $1.3 \times 10^{-04}$ & 0.002\\
SAMD9L & Neutropenia [HP:0001875] & Arg986Cys & 7/9 (78\%) & Ser626Leu & 0/9 (0\%) & 0.002 & 0.008\\
SAMD9L & Pancytopenia [HP:0001876] & Arg986Cys & 4/6 (67\%) & Ser626Leu & 0/9 (0\%) & 0.011 & 0.026\\
SAMD9L & Thrombocytopenia [HP:0001873] & Arg986Cys & 7/9 (78\%) & Ser626Leu & 0/9 (0\%) & 0.002 & 0.008\\
SATB2 & Cleft palate [HP:0000175] & missense & 11/49 (22\%) & $^{\complement}$ & 59/105 (56\%) & $1.1 \times 10^{-04}$ & 0.002\\
SCN2A & Intellectual disability [HP:0001249] & I repeat & 21/42 (50\%) & $^{\complement}$ & 157/190 (83\%) & $2.6 \times 10^{-05}$ & $4.2 \times 10^{-04}$\\
SCN2A & Neurodevelopmental abnormality [HP:0012759] & I repeat & 48/65 (74\%) & $^{\complement}$ & 198/218 (91\%) & $1.0 \times 10^{-03}$ & 0.009\\
SCN2A & Autism [HP:0000717] & missense & 59/146 (40\%) & $^{\complement}$ & 33/43 (77\%) & $2.7 \times 10^{-05}$ & $8.6 \times 10^{-05}$\\
SCN2A & Focal-onset seizure [HP:0007359] & missense & 141/170 (83\%) & $^{\complement}$ & 8/33 (24\%) & $8.7 \times 10^{-11}$ & $6.9 \times 10^{-10}$\\
SCN2A & Generalized-onset seizure [HP:0002197] & missense & 104/133 (78\%) & $^{\complement}$ & 6/31 (19\%) & $1.4 \times 10^{-09}$ & $5.7 \times 10^{-09}$\\
SCN2A & Intellectual disability [HP:0001249] & missense & 144/198 (73\%) & $^{\complement}$ & 34/34 (100\%) & $9.4 \times 10^{-05}$ & $2.5 \times 10^{-04}$\\
SCN2A & Motor seizure [HP:0020219] & missense & 146/175 (83\%) & $^{\complement}$ & 6/31 (19\%) & $4.5 \times 10^{-12}$ & $7.2 \times 10^{-11}$\\
SCN2A & Neurodevelopmental abnormality [HP:0012759] & missense & 201/238 (84\%) & $^{\complement}$ & 45/45 (100\%) & $1.0 \times 10^{-03}$ & 0.003\\
SCN2A & Seizure [HP:0001250] & missense & 298/327 (91\%) & $^{\complement}$ & 28/53 (53\%) & $1.6 \times 10^{-10}$ & $8.4 \times 10^{-10}$\\
SCO2 & Hypertrophic cardiomyopathy [HP:0001639] & p.Glu140Lys/ p.Glu140Lys & 2/6 (33\%) & $^{\complement}$/$^{\complement}$ OR p.Glu140Lys/$^{\complement}$ & 13/13 (100\%) & 0.004 & 0.027\\
SETD2 & Delayed ability to walk [HP:0031936] & p.Arg1740Trp & 8/8 (100\%) & $^{\complement}$ & 1/10 (10\%) & $4.1 \times 10^{-04}$ & 0.003\\
SETD2 & Hypertelorism [HP:0000316] & p.Arg1740Trp & 11/11 (100\%) & $^{\complement}$ & 5/23 (22\%) & $1.5 \times 10^{-05}$ & $2.6 \times 10^{-04}$\\
SETD2 & Macrocephaly [HP:0000256] & p.Arg1740Trp & 0/11 (0\%) & $^{\complement}$ & 19/28 (68\%) & $1.5 \times 10^{-04}$ & 0.002\\
SETD2 & Scoliosis [HP:0002650] & p.Arg1740Trp & 6/6 (100\%) & $^{\complement}$ & 2/14 (14\%) & $7.2 \times 10^{-04}$ & 0.005\\
SETD2 & Severe global developmental delay [HP:0011344] & p.Arg1740Trp & 9/9 (100\%) & $^{\complement}$ & 0/12 (0\%) & $3.4 \times 10^{-06}$ & $1.2 \times 10^{-04}$\\
SETD2 & Ventriculomegaly [HP:0002119] & p.Arg1740Trp & 4/4 (100\%) & $^{\complement}$ & 2/17 (12\%) & 0.003 & 0.012\\
SETD2 & Wide nasal bridge [HP:0000431] & p.Arg1740Trp & 9/9 (100\%) & $^{\complement}$ & 2/9 (22\%) & 0.002 & 0.012\\
SETD2 & Macrocephaly [HP:0000256] & missense & 4/24 (17\%) & $^{\complement}$ & 15/15 (100\%) & $1.5 \times 10^{-07}$ & $6.3 \times 10^{-06}$\\
SMAD3 & Osteoarthritis [HP:0002758] & p.Arg287Trp & 19/19 (100\%) & $^{\complement}$ & 7/19 (37\%) & $3.7 \times 10^{-05}$ & $8.6 \times 10^{-04}$\\
SMARCB1 & Atypical teratoid/rhabdoid tumor [HP:0034401] & SV & 8/9 (89\%) & $^{\complement}$ & 2/19 (11\%) & $1.2 \times 10^{-04}$ & $5.9 \times 10^{-04}$\\
SMARCB1 & Embryonal neoplasm [HP:0002898] & SV & 8/8 (100\%) & $^{\complement}$ & 2/19 (11\%) & $2.0 \times 10^{-05}$ & $1.5 \times 10^{-04}$\\
SMARCB1 & Neoplasm by anatomical site [HP:0011793] & SV & 3/3 (100\%) & $^{\complement}$ & 3/20 (15\%) & 0.011 & 0.028\\
SMARCB1 & Neoplasm by histology [HP:0011792] & SV & 11/11 (100\%) & $^{\complement}$ & 4/21 (19\%) & $1.1 \times 10^{-05}$ & $1.5 \times 10^{-04}$\\
SMARCB1 & Neuroepithelial neoplasm [HP:0030063] & SV & 2/2 (100\%) & $^{\complement}$ & 0/17 (0\%) & 0.006 & 0.018\\
SMARCB1 & Rhabdoid tumor [HP:0034557] & SV & 4/4 (100\%) & $^{\complement}$ & 2/19 (11\%) & 0.002 & 0.006\\
SMARCC2 & Intellectual disability [HP:0001249] & c.3222del & 1/6 (17\%) & $^{\complement}$ & 49/52 (94\%) & $7.0 \times 10^{-05}$ & 0.006\\
SPTAN1 & Appendicular spasticity [HP:0034353] & Arg19Trp & 21/21 (100\%) & $^{\complement}$ & 2/15 (13\%) & $4.5 \times 10^{-08}$ & $1.9 \times 10^{-07}$\\
SPTAN1 & Distal lower limb muscle weakness [HP:0009053] & Arg19Trp & 8/15 (53\%) & $^{\complement}$ & 1/20 (5\%) & 0.002 & 0.004\\
SPTAN1 & Epileptic spasm [HP:0011097] & Arg19Trp & 0/19 (0\%) & $^{\complement}$ & 15/20 (75\%) & $7.7 \times 10^{-07}$ & $2.7 \times 10^{-06}$\\
SPTAN1 & Infantile spasms [HP:0012469] & Arg19Trp & 0/19 (0\%) & $^{\complement}$ & 15/41 (37\%) & $1.0 \times 10^{-03}$ & 0.003\\
SPTAN1 & Intellectual disability [HP:0001249] & Arg19Trp & 0/21 (0\%) & $^{\complement}$ & 27/34 (79\%) & $1.8 \times 10^{-09}$ & $1.5 \times 10^{-08}$\\
SPTAN1 & Lower limb muscle weakness [HP:0007340] & Arg19Trp & 14/14 (100\%) & $^{\complement}$ & 17/30 (57\%) & 0.003 & 0.007\\
SPTAN1 & Lower limb spasticity [HP:0002061] & Arg19Trp & 21/21 (100\%) & $^{\complement}$ & 0/13 (0\%) & $1.1 \times 10^{-09}$ & $1.4 \times 10^{-08}$\\
SPTAN1 & Microcephaly [HP:0000252] & Arg19Trp & 0/21 (0\%) & $^{\complement}$ & 19/45 (42\%) & $2.4 \times 10^{-04}$ & $6.1 \times 10^{-04}$\\
SPTAN1 & Motor axonal neuropathy [HP:0007002] & Arg19Trp & 0/16 (0\%) & $^{\complement}$ & 12/19 (63\%) & $6.3 \times 10^{-05}$ & $1.7 \times 10^{-04}$\\
SPTAN1 & Motor seizure [HP:0020219] & Arg19Trp & 0/19 (0\%) & $^{\complement}$ & 20/25 (80\%) & $3.3 \times 10^{-08}$ & $1.7 \times 10^{-07}$\\
SPTAN1 & Peripheral axonal neuropathy [HP:0003477] & Arg19Trp & 4/20 (20\%) & $^{\complement}$ & 12/19 (63\%) & 0.010 & 0.017\\
SPTAN1 & Seizure [HP:0001250] & Arg19Trp & 2/21 (10\%) & $^{\complement}$ & 35/40 (88\%) & $2.4 \times 10^{-09}$ & $1.5 \times 10^{-08}$\\
SPTAN1 & Spastic paraplegia [HP:0001258] & Arg19Trp & 21/21 (100\%) & $^{\complement}$ & 0/20 (0\%) & $3.7 \times 10^{-12}$ & $9.3 \times 10^{-11}$\\
SPTAN1 & Spasticity [HP:0001257] & Arg19Trp & 21/21 (100\%) & $^{\complement}$ & 5/18 (28\%) & $1.0 \times 10^{-06}$ & $3.3 \times 10^{-06}$\\
SPTAN1 & Appendicular spasticity [HP:0034353] & missense & 21/22 (95\%) & $^{\complement}$ & 2/14 (14\%) & $8.7 \times 10^{-07}$ & $8.1 \times 10^{-06}$\\
SPTAN1 & Distal lower limb muscle weakness [HP:0009053] & missense & 9/19 (47\%) & $^{\complement}$ & 0/16 (0\%) & $1.0 \times 10^{-03}$ & 0.004\\
SPTAN1 & Epileptic spasm [HP:0011097] & missense & 2/22 (9\%) & $^{\complement}$ & 13/17 (76\%) & $2.9 \times 10^{-05}$ & $1.4 \times 10^{-04}$\\
SPTAN1 & Infantile spasms [HP:0012469] & missense & 2/29 (7\%) & $^{\complement}$ & 13/31 (42\%) & 0.002 & 0.005\\
SPTAN1 & Intellectual disability [HP:0001249] & missense & 9/32 (28\%) & $^{\complement}$ & 18/23 (78\%) & $3.4 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
SPTAN1 & Lower limb muscle weakness [HP:0007340] & missense & 15/16 (94\%) & $^{\complement}$ & 16/28 (57\%) & 0.015 & 0.030\\
SPTAN1 & Lower limb spasticity [HP:0002061] & missense & 21/22 (95\%) & $^{\complement}$ & 0/12 (0\%) & $2.4 \times 10^{-08}$ & $6.6 \times 10^{-07}$\\
SPTAN1 & Microcephaly [HP:0000252] & missense & 4/34 (12\%) & $^{\complement}$ & 15/32 (47\%) & 0.002 & 0.005\\
SPTAN1 & Motor axonal neuropathy [HP:0007002] & missense & 0/19 (0\%) & $^{\complement}$ & 12/16 (75\%) & $2.2 \times 10^{-06}$ & $1.5 \times 10^{-05}$\\
SPTAN1 & Motor seizure [HP:0020219] & missense & 7/27 (26\%) & $^{\complement}$ & 13/17 (76\%) & 0.002 & 0.004\\
SPTAN1 & Peripheral axonal neuropathy [HP:0003477] & missense & 4/23 (17\%) & $^{\complement}$ & 12/16 (75\%) & $6.7 \times 10^{-04}$ & 0.002\\
SPTAN1 & Seizure [HP:0001250] & missense & 13/33 (39\%) & $^{\complement}$ & 24/28 (86\%) & $2.5 \times 10^{-04}$ & $9.9 \times 10^{-04}$\\
SPTAN1 & Spastic paraplegia [HP:0001258] & missense & 21/25 (84\%) & $^{\complement}$ & 0/16 (0\%) & $4.7 \times 10^{-08}$ & $6.6 \times 10^{-07}$\\
SPTAN1 & Spasticity [HP:0001257] & missense & 22/23 (96\%) & $^{\complement}$ & 4/16 (25\%) & $5.2 \times 10^{-06}$ & $2.9 \times 10^{-05}$\\
SPTAN1 & Appendicular spasticity [HP:0034353] & truncating & 0/8 (0\%) & $^{\complement}$ & 23/28 (82\%) & $4.3 \times 10^{-05}$ & $2.7 \times 10^{-04}$\\
SPTAN1 & Hypotonia [HP:0001252] & truncating & 1/11 (9\%) & $^{\complement}$ & 15/24 (62\%) & 0.004 & 0.015\\
SPTAN1 & Lower limb spasticity [HP:0002061] & truncating & 0/8 (0\%) & $^{\complement}$ & 21/26 (81\%) & $7.1 \times 10^{-05}$ & $3.5 \times 10^{-04}$\\
SPTAN1 & Motor axonal neuropathy [HP:0007002] & truncating & 12/12 (100\%) & $^{\complement}$ & 0/23 (0\%) & $1.2 \times 10^{-09}$ & $3.0 \times 10^{-08}$\\
SPTAN1 & Peripheral axonal neuropathy [HP:0003477] & truncating & 12/12 (100\%) & $^{\complement}$ & 4/27 (15\%) & $4.6 \times 10^{-07}$ & $5.8 \times 10^{-06}$\\
SPTAN1 & Spastic paraplegia [HP:0001258] & truncating & 0/8 (0\%) & $^{\complement}$ & 21/33 (64\%) & $1.0 \times 10^{-03}$ & 0.005\\
SPTAN1 & Spasticity [HP:0001257] & truncating & 0/8 (0\%) & $^{\complement}$ & 26/31 (84\%) & $2.1 \times 10^{-05}$ & $1.7 \times 10^{-04}$\\
SUOX & Microcephaly [HP:0000252] & homodimerization/ homodimerization OR homodimerization/$^{\complement}$ & 0/9 (0\%) & $^{\complement}$/$^{\complement}$ & 10/12 (83\%) & $2.2 \times 10^{-04}$ & 0.003\\
TBCK & Developmental regression [HP:0002376] & R126*/R126* & 9/12 (75\%) & R126*/$^{\complement}$ OR $^{\complement}$/$^{\complement}$ & 2/22 (9\%) & $1.8 \times 10^{-04}$ & 0.003\\
TBCK & Macroglossia [HP:0000158] & R126*/R126* & 11/12 (92\%) & R126*/$^{\complement}$ OR $^{\complement}$/$^{\complement}$ & 3/22 (14\%) & $1.3 \times 10^{-05}$ & $4.3 \times 10^{-04}$\\
TBX1 & Global developmental delay [HP:0001263] & Tyr418PhefsTer42 & 5/5 (100\%) & $^{\complement}$ & 3/20 (15\%) & $1.0 \times 10^{-03}$ & 0.023\\
TBX1 & Narrow nose [HP:0000460] & Tyr418PhefsTer42 & 5/5 (100\%) & $^{\complement}$ & 0/6 (0\%) & 0.002 & 0.024\\
TBX5 & Upper limb phocomelia [HP:0009813] & Arg237Gln & 7/22 (32\%) & $^{\complement}$ & 3/131 (2\%) & $4.6 \times 10^{-05}$ & $7.3 \times 10^{-04}$\\
TBX5 & Ventricular septal defect [HP:0001629] & Arg237Gln & 0/17 (0\%) & $^{\complement}$ & 61/73 (84\%) & $5.6 \times 10^{-11}$ & $1.8 \times 10^{-09}$\\
TBX5 & Ventricular septal defect [HP:0001629] & missense & 31/60 (52\%) & $^{\complement}$ & 30/30 (100\%) & $4.6 \times 10^{-07}$ & $1.5 \times 10^{-05}$\\
TGFBR1 & Self-healing squamous epithelioma [HP:0034720] & Gly52Arg & 7/7 (100\%) & $^{\complement}$ & 11/33 (33\%) & 0.002 & 0.012\\
TGFBR1 & Arterial tortuosity [HP:0005116] & MSSE var & 1/19 (5\%) & $^{\complement}$ & 8/16 (50\%) & 0.005 & 0.026\\
TGFBR1 & Hypertelorism [HP:0000316] & MSSE var & 0/18 (0\%) & $^{\complement}$ & 15/19 (79\%) & $5.0 \times 10^{-07}$ & $4.0 \times 10^{-06}$\\
TGFBR1 & Self-healing squamous epithelioma [HP:0034720] & MSSE var & 18/19 (95\%) & $^{\complement}$ & 0/21 (0\%) & $1.7 \times 10^{-10}$ & $2.7 \times 10^{-09}$\\
UMOD & Hyperuricemia [HP:0002149] & EGF & 14/32 (44\%) & $^{\complement}$ & 50/57 (88\%) & $1.8 \times 10^{-05}$ & $1.1 \times 10^{-04}$\\
UMOD & Hyperuricemia [HP:0002149] & cysteine & 38/41 (93\%) & $^{\complement}$ & 26/48 (54\%) & $4.5 \times 10^{-05}$ & $2.7 \times 10^{-04}$\\
WWOX & Bilateral tonic-clonic seizure with focal onset [HP:0007334] & MAPT Interaction/MAPT Interaction OR MAPT Interaction/$^{\complement}$ & 0/18 (0\%) & $^{\complement}$/$^{\complement}$ & 7/9 (78\%) & $4.1 \times 10^{-05}$ & 0.002\\
ZFX & Hyperparathyroidism [HP:0000843] & missense & 7/9 (78\%) & $^{\complement}$ & 0/5 (0\%) & 0.021 & 0.021\\
ZMYM3 & Cupped ear [HP:0000378] & R441 & 7/10 (70\%) & $^{\complement}$ & 1/23 (4\%) & $2.0 \times 10^{-04}$ & 0.012\\
\hline
\end{longtable}
\end{scriptsize}
\end{center}